Amino-pyrimidine cyclo-amides
The invention provides novel compounds having the general formula (I) wherein R 1 , R 2 , R 3 and n are as defined herein, compositions including methods of making the compounds and using the compounds as ATX inhibitors.
1 . A compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is selected from the group consisting of
i) H,
ii) C 1-6 -alkyl,
iii) C 3-8 -cycloalkyl,
iv) C 3-8 -cycloalkylalkyl,
v) C 1-6 -alkoxy,
vi) C 1-6 -alkoxy-C 1-6 -alkyl,
vii) heterocycloalkyl,
viii) heterocycloalkylalkyl,
ix) substituted C 3-8 -cycloalkyl,
x) substituted C 3-8 -cycloalkylalkyl,
xi) substituted heterocycloalkyl,
xii) substituted heterocycloalkylalkyl,
xiii) halo-C 1-6 -alkyl, and
xiv) hydroxy-C 1-6 -alkyl,
wherein substituted C 3-8 -cycloalkyl or substituted heterocycloalkyl are substituted with one or more substituents selected from the group consisting of H, C 1-6 -alkyl, halogen, hydroxy, and C 1-6 -carbonyl;
R 2 is selected from the group consisting of
i) H,
ii) halogen,
iii) halo-C 1-6 -alkyl,
iv) C 1-6 -alkyl, and
v) cyano,
wherein at least one of R 1 and R 2 is other than H;
R 3 is selected from the group consisting of
i) H, and
ii) halogen; and
n is 0 or 1.
2 . A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is halogen.
3 . A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is Cl.
4 . A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is selected from the group consisting of
i) H, and
ii) cyano.
5 . A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group consisting of
i) H,
ii) C 1-6 -alkyl,
iii) C 3-8 -cycloalkyl,
iv) C 3-8 -cycloalkylalkyl,
v) C 1-6 -alkoxy,
vi) C 1-6 -alkoxy-C 1-6 -alkyl,
vii) heterocycloalkyl,
viii) heterocycloalkylalkyl,
ix) substituted C 3-8 -cycloalkyl,
x) substituted C 3-8 -cycloalkylalkyl,
xi) substituted heterocycloalkyl,
xii) substituted heterocycloalkylalkyl,
xiii) halo-C 1-6 -alkyl, and
xiv) hydroxy-C 1-6 -alkyl,
wherein substituted C 3-8 -cycloalkyl or substituted heterocycloalkyl are substituted with one or more substituents selected from the group consisting of H, C 1-6 -alkyl, halogen, hydroxy, and C 1-6 -carbonyl; and
wherein heterocycloalkyl is a 4-6 atom ring system comprising one heteroatom selected from N and O.
6 . A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is Cl, R 2 is H or cyano, and R 1 is selected from the group consisting of
i) H,
ii) C 1-6 -alkyl,
iii) C 3-8 -cycloalkyl,
iv) C 3-8 -cycloalkylalkyl,
v) C 1-6 -alkoxy,
vi) C 1-6 -alkoxy-C 1-6 -alkyl,
vii) heterocycloalkyl,
viii) heterocycloalkylalkyl,
ix) substituted C 3-8 -cycloalkyl,
x) substituted C 3-8 -cycloalkylalkyl,
xi) substituted heterocycloalkyl,
xii) substituted heterocycloalkylalkyl,
xiii) halo-C 1-6 -alkyl, and
xiv) hydroxy-C 1-6 -alkyl,
wherein substituted C 3-8 -cycloalkyl or substituted heterocycloalkyl are substituted with one or more substituents selected from the group consisting of H, C 1-6 -alkyl, halogen, hydroxy, and C 1-6 -carbonyl;
wherein heterocycloalkyl is a 4-6 atom ring system comprising one heteroatom selected from N and O;
wherein at least one of R 1 and R 2 is other than H; and
n is 0 or 1.
7 . A compound according to claim 1 , selected from the group consisting of
2-((5-chloro-2,3-dihydro-1H-inden-2-yl)amino)-6-(oxetan-3-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;
2-((5-chloro-2,3-dihydro-1H-inden-2-yl)amino)-6-(3-methyloxetan-3-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;
(S)-6-chloro-2-((6-(3-methyloxetan-3-yl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
2-((5-chloro-2,3-dihydro-1H-inden-2-yl)amino)-6-(6,6-difluorospiro[3.3]heptan-2-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;
2-((5-chloro-2,3-dihydro-1H-inden-2-yl)amino)-6-(3,3-difluorocyclobutyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;
(S)-6-chloro-2-((6-(3,3-difluoro-1-methylcyclobutyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-(6,6-difluorospiro[3.3]heptan-2-yl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-(3,3-difluorocyclobutyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((5-oxo-6-(tetrahydro-2H-pyran-4-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((5-oxo-6-(2,2,2-trifluoroethyl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S,S) and (S,R)-6-chloro-2-((5-oxo-6-(tetrahydrofuran-3-yl)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-isopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-cyclopropyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-(oxetan-3-ylmethyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-(1-methylcyclopropyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-(oxetan-3-yl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-(oxetan-3-yl)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-(cyclopropylmethyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-((1r,3S)-3-hydroxycyclobutyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-(2-methoxyethyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-(2-hydroxy-2-methylpropyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-(2-fluoroethyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-methyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-((1-hydroxycyclopropyl)methyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-2-((6-(1-acetylpiperidin-4-yl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-6-chloro-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-(1,3-difluoropropan-2-yl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-((3-methyloxetan-3-yl)methyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((5-oxo-6-(tetrahydro-2H-pyran-4-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-isopropyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-(cyclopropylmethyl)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S,S) and (S,R) 6-chloro-2-((5-oxo-6-(tetrahydrofuran-3-yl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-ethyl-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((6-ethyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
(S)-6-chloro-2-((5-oxo-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile; and
(S)-6-chloro-2-((5-oxo-6-(2,2,2-trifluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)amino)-2,3-dihydro-1H-indene-4-carbonitrile;
or a pharmaceutically acceptable salt thereof.
8 . A process to prepare a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, the process comprising the reaction of a compound of formula (II) in the presence of a compound of formula (III) to provide a compound of formula (I), wherein R 1 , R 2 , R 3 , and n are as defined in claim 1 :
9 . A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.